Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izokibep in moderate to severe hidradenitis suppurativa
NCT05355805Phase 2Completed
- Sponsor
- Acelyrin
- Start
- May 2022
- Primary completion
- Aug 2023
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 2 trial of izokibep in hidradenitis suppurativa (HS), sponsored by Acelyrin. Started May 2022; status: completed.
02
Drugs
izokibep
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05355805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355805.